Gilead Sciences Inc.'s and Galapagos NV's view that filgotinib has considerable potential as a treatment for range of inflammatory diseases has been supported by more clinical progress for the oral Janus kinase (JAK) inhibitor, this time in psoriatic arthritis (PsA) and ulcerative colitis (UC).
First up, the firms unveiled data from the Phase II EQUATOR study which showed filgotinib achieved its primary endpoint of improvement in the signs and symptoms of PsA at week 16, as assessed by the American College of Rheumatology 20% improvement score